Try our Advanced Search for more refined results

FDA Wants More Info On New Schizophrenia Drug Trials

By Dani Kass (May 1, 2017, 3:26 PM EDT) -- The U.S. Food and Drug Administration has asked for more information on clinical trials related to Intra-Cellular Therapies Inc.'s new schizophrenia medication lumateperone, but the company on Monday said it still could have the drug submitted for approval by the middle of 2018 despite the setback....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!